Yeast-Derived β-Glucan in Combination with Anti-Tumor Monoclonal Antibody Therapy in Cancer

Author(s): Jingjing Liu, Lacey Gunn, Richard Hansen, Jun Yan.

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 4 , Issue 2 , 2009

Become EABM
Become Reviewer

Abstract:

β-Glucans are cell wall constituents of many plants and microorganisms. However, β-glucans are not expressed on mammalian cells and are recognized as pathogen-associated molecular patterns by pattern recognition receptors. β- Glucans have been used to treat cancer and infectious disease for many years as biological response modifiers with varying and unpredictable efficacy. Recent studies have demonstrated the mechanism of action of yeast-derived β-glucan in combination with anti-tumor monoclonal antibodies in cancer therapy. in vitro and in vivo Data indicate that successful combination therapy requires complement activation and iC3b deposition on tumors and complement receptor 3 (CR3) expression on granulocytes. The defined effector cells are CR3+ neutrophils. This review provides a brief overview of this combination therapy in cancer and describes in detail the β-glucan composition and receptors, mechanism of action, and preclinical studies in human carcinoma xenograft models. Current and future developments are also discussed to provide our own point of view on this combination therapy in potential clinical investigations. Relevant patents are discussed.

Keywords: Anti-tumor monoclonal antibody, β-glucan, immunotherapy, complement receptor, neutrophils, complement regulatory proteins

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 4
ISSUE: 2
Year: 2009
Page: [101 - 109]
Pages: 9
DOI: 10.2174/157489209788452858
Price: $58

Article Metrics

PDF: 14